dapagliflozin 5 MG Oral Tablet [Farxiga]

RxCUI: 1486981
RxNorm name: dapagliflozin 5 MG Oral Tablet [Farxiga]
Display name: FARXIGA (Oral Pill)
Full name: dapagliflozin 5 MG Oral Tablet [Farxiga]
Term type: SBD
Status: Active
Strength: 5 mg
Dose form: Tab
Route: Oral Pill
Updated: 2026-08-18 06:17:59

RxNorm Status History#

Status: Active
Source: RXNORM
Current: YES
Release start: 022014
Active start: 022014
Multiple ingredient: NO
Branded: YES

Ingredients And Strength#

Ingredient, Strength, Base table
Ingredient	Strength	Base	Basis of strength
dapagliflozin	5 MG / 1 EACH	dapagliflozin	dapagliflozin

Dose Form Concepts#

Dose form, RxCUI table
Dose form	RxCUI
Oral Tablet	317541

Derived Ingredient Concepts#

Ingredient, RxCUI table
Ingredient	RxCUI
dapagliflozin	1488564

Source Vocabulary Codes#

Code type, Values, Count table
Code type	Values	Count	Category
PRESCRIBABLE	Y	1	ATTRIBUTES
RXNAV_STR	Farxiga 5 MG Oral Tablet	1	NAMES
RxNorm Name	dapagliflozin 5 MG Oral Tablet [Farxiga]	1	NAMES
RxNorm Synonym	Farxiga 5 MG Oral Tablet	1	NAMES
TTY	SBD	1	ATTRIBUTES
SPL_SET_ID	3 linked values 01f90c94-71cb-4a1f-81ff-8004b850529b 72ad22ae-efe6-4cd6-a302-98aaee423d69 ef9e9c8c-5460-4193-952a-0c249dd071bd	3	CODES
RxCUI	1486981	1	CODES
MMSL_CODE	BD28022	1	CODES

FDA NDC Products And Packages#

Package NDC, Product NDC, Name table
Package NDC	Product NDC	Name	Labeler	Application
0310-6205-30	0310-6205	FARXIGA DAPAGLIFLOZIN	AstraZeneca Pharmaceuticals LP	NDA202293
0310-6205-90	0310-6205	FARXIGA DAPAGLIFLOZIN	AstraZeneca Pharmaceuticals LP	NDA202293
0310-6205-95	0310-6205	FARXIGA DAPAGLIFLOZIN	AstraZeneca Pharmaceuticals LP	NDA202293
50090-3482-0	50090-3482	FARXIGA DAPAGLIFLOZIN	A-S Medication Solutions	NDA202293
70518-4614-0	70518-4614	FARXIGA DAPAGLIFLOZIN	REMEDYREPACK INC.	NDA202293

Drugs@FDA Applications#

Application, NDC, Name table
Application	NDC	Name	Marketing category	Labeler
NDA202293	0310-6205	FARXIGA DAPAGLIFLOZIN	NDA	AstraZeneca Pharmaceuticals LP

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 12 matching rows.

NDC11, Source, Active table
NDC11	Source	Active
00310620530	rxnav_ndcs	yes
00310620590	rxnav_ndcs	yes
00310620595	rxnav_ndcs	yes
50090348200	rxnav_ndcs	yes
70518461400	rxnav_ndcs	yes
70518461401	rxnav_ndcs	yes
00003142711	rxnav_historical
00003142712	rxnav_historical
00003142713	rxnav_historical
00003142714	rxnav_historical
00003142791	rxnav_historical
55154693208	rxnav_historical

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 3 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
FARXIGA	DAPAGLIFLOZIN	A-S Medication Solutions	01f90c94-71cb-4a1f-81ff-8004b850529b	2026-07-10	Warnings, Adverse reactions	Exact identifier ndc (package): 50090-3482-0 ndc (product): 50090-3482 ndc11 (package): 50090348200 rxcui: 1486981
FARXIGA	DAPAGLIFLOZIN	AstraZeneca Pharmaceuticals LP	72ad22ae-efe6-4cd6-a302-98aaee423d69	2026-06-03	Warnings, Adverse reactions	Exact identifier ndc (package): 0310-6205-95 ndc (package): 0310-6205-30 ndc (package): 0310-6205-90 ndc (product): 0310-6205 ndc11 (package): 00310620590 ndc11 (package): 00310620530 ndc11 (package): 00310620595 rxcui: 1486981
FARXIGA	DAPAGLIFLOZIN	REMEDYREPACK INC.	ef9e9c8c-5460-4193-952a-0c249dd071bd	2026-04-24	Warnings, Adverse reactions	Exact identifier ndc (package): 70518-4614-0 ndc (product): 70518-4614 ndc11 (package): 70518461400 ndc11 (package): 70518461401 rxcui: 1486981

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 4 matching rows.

Set ID, RxNorm mappings, Terms table
Set ID	RxNorm mappings	Terms	SPL version	Label	Effective
72ad22ae-efe6-4cd6-a302-98aaee423d69	farxiga 5 MG Oral Tablet [PSN] · dapagliflozin 5 MG Oral Tablet [Farxiga] [SBD] · Farxiga 5 MG Oral Tablet [SY]	3	45	These highlights do not include all the information needed to use FARXIGA safely and effectively. See full prescribing information for FARXIGA. FARXIGA ® (dapagliflozin) tablets, for oral use Initial U.S. Approval: 2014	20241024
40cc4f5d-bcf6-4016-9d1e-838bbc4bdddc	farxiga 5 MG Oral Tablet [PSN] · dapagliflozin 5 MG Oral Tablet [Farxiga] [SBD] · Farxiga 5 MG Oral Tablet [SY]	3	20	These highlights do not include all the information needed to use FARXIGA safely and effectively. See full prescribing information for FARXIGA. FARXIGA ® (dapagliflozin) tablets, for oral use Initial U.S. Approval: 2014	20240829
01f90c94-71cb-4a1f-81ff-8004b850529b	farxiga 5 MG Oral Tablet [PSN] · dapagliflozin 5 MG Oral Tablet [Farxiga] [SBD] · Farxiga 5 MG Oral Tablet [SY]	3	15	These highlights do not include all the information needed to use FARXIGA safely and effectively. See full prescribing information for FARXIGA. FARXIGA ® (dapagliflozin) tablets, for oral use Initial U.S. Approval: 2014	20231212
ef9e9c8c-5460-4193-952a-0c249dd071bd	farxiga 5 MG Oral Tablet [PSN] · dapagliflozin 5 MG Oral Tablet [Farxiga] [SBD] · Farxiga 5 MG Oral Tablet [SY]	3	1	These highlights do not include all the information needed to use FARXIGA safely and effectively. See full prescribing information for FARXIGA. FARXIGA ® (dapagliflozin) tablets, for oral use Initial U.S. Approval: 2014	20260424

Recently Linked DailyMed Labels#

Set ID, Title, Manufacturer table
Set ID	Title	Manufacturer	Effective
01f90c94-71cb-4a1f-81ff-8004b850529b	These highlights do not include all the information needed to use FARXIGA safely and effectively. See full prescribing information for FARXIGA. FARXIGA ® (dapagliflozin) tablets, for oral use Initial U.S. Approval: 2014	A-S Medication Solutions	20260710
72ad22ae-efe6-4cd6-a302-98aaee423d69	These highlights do not include all the information needed to use FARXIGA safely and effectively. See full prescribing information for FARXIGA. FARXIGA ® (dapagliflozin) tablets, for oral use Initial U.S. Approval: 2014	AstraZeneca Pharmaceuticals LP	20260603
ef9e9c8c-5460-4193-952a-0c249dd071bd	These highlights do not include all the information needed to use FARXIGA safely and effectively. See full prescribing information for FARXIGA. FARXIGA ® (dapagliflozin) tablets, for oral use Initial U.S. Approval: 2014	REMEDYREPACK INC.	20260424
72ad22ae-efe6-4cd6-a302-98aaee423d69	These highlights do not include all the information needed to use FARXIGA safely and effectively. See full prescribing information for FARXIGA. FARXIGA ® (dapagliflozin) tablets, for oral use Initial U.S. Approval: 2014	AstraZeneca Pharmaceuticals LP	20251222
72ad22ae-efe6-4cd6-a302-98aaee423d69	These highlights do not include all the information needed to use FARXIGA safely and effectively. See full prescribing information for FARXIGA. FARXIGA ® (dapagliflozin) tablets, for oral use Initial U.S. Approval: 2014	AstraZeneca Pharmaceuticals LP	20241024
40cc4f5d-bcf6-4016-9d1e-838bbc4bdddc	These highlights do not include all the information needed to use FARXIGA safely and effectively. See full prescribing information for FARXIGA. FARXIGA ® (dapagliflozin) tablets, for oral use Initial U.S. Approval: 2014	Cardinal Health 107, LLC	20240829
01f90c94-71cb-4a1f-81ff-8004b850529b	These highlights do not include all the information needed to use FARXIGA safely and effectively. See full prescribing information for FARXIGA. FARXIGA ® (dapagliflozin) tablets, for oral use Initial U.S. Approval: 2014	A-S Medication Solutions	20231212

Drug Classes#

Source, Class ID, Class table
Source	Class ID	Class	Type	Relationship	Drug concept
ATC	A10BK	Sodium-glucose co-transporter 2 (SGLT2) inhibitors	ATC1-4		dapagliflozin
FDASPL	N0000187059	Sodium-Glucose Cotransporter 2 Inhibitor	EPC	has_epc	dapagliflozin
FDASPL	N0000187058	Sodium-Glucose Transporter 2 Inhibitors	MOA	has_moa	dapagliflozin
MEDRT	D001559	Benzhydryl Compounds	CHEM	has_ingredient	dapagliflozin
MEDRT	D005960	Glucosides	CHEM	has_ingredient	dapagliflozin
MEDRT	D003924	Diabetes Mellitus, Type 2	DISEASE	may_treat	dapagliflozin
MEDRT	D006333	Heart Failure	DISEASE	may_treat	dapagliflozin
MEDRT	N0000187058	Sodium-Glucose Transporter 2 Inhibitors	MOA	has_moa	dapagliflozin
MEDRT	N0000175650	Decreased Sympathetic Activity	PE	has_pe	dapagliflozin
MEDRT	N0000009556	Increased Renal Organic Ion Excretion	PE	has_pe	dapagliflozin
MEDRT	N0000009830	Renal Ion Transport Alteration	PE	has_pe	dapagliflozin

Group, Type, Concept table
Group	Type	Concept	Source
BN	BN	Farxiga	rxnav_allrelated
DF	DF	Oral Tablet	rxnav_allrelated
DFG	DFG	Oral Product	rxnav_allrelated
DFG	DFG	Pill	rxnav_allrelated
IN	IN	dapagliflozin	rxnav_allrelated
SBD	SBD	dapagliflozin 5 MG Oral Tablet [Farxiga]	rxnav_allrelated
SBDC	SBDC	dapagliflozin 5 MG [Farxiga]	rxnav_allrelated
SBDF	SBDF	dapagliflozin Oral Tablet [Farxiga]	rxnav_allrelated
SBDG	SBDG	Farxiga Oral Product	rxnav_allrelated
SBDG	SBDG	Farxiga Pill	rxnav_allrelated
SCD	SCD	dapagliflozin 5 MG Oral Tablet	rxnav_allrelated
SCDC	SCDC	dapagliflozin 5 MG	rxnav_allrelated
SCDF	SCDF	dapagliflozin Oral Tablet	rxnav_allrelated
SCDG	SCDG	dapagliflozin Oral Product	rxnav_allrelated
SCDG	SCDG	dapagliflozin Pill	rxnav_allrelated

Properties#

Category, Property, Value table
Category	Property	Value
ATTRIBUTES	AVAILABLE_STRENGTH	5 MG
ATTRIBUTES	GENERAL_CARDINALITY	SINGLE
ATTRIBUTES	HUMAN_DRUG	US
ATTRIBUTES	RXNAV_HUMAN_DRUG	US
ATTRIBUTES	SCHEDULE	0
CODES	NDA	NDA202293
NAMES	Prescribable Synonym	farxiga 5 MG Oral Tablet
SOURCES	Source	Gold Standard Alchemy
SOURCES	Source	Metathesaurus FDA Structured Product Labels
SOURCES	Source	Micromedex RED BOOK
SOURCES	Source	Multum MediSource Lexicon